The Ludwig Branch for Cancer Research of the University of Lausanne, Epalinges.
Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Ann Oncol. 2017 Dec 1;28(suppl_12):xii18-xii32. doi: 10.1093/annonc/mdx238.
T-lymphocytes play a critical role in cancer immunity as evidenced by their presence in resected tumor samples derived from long-surviving patients, and impressive clinical responses to various immunotherapies that reinvigorate them. Indeed, tumors can upregulate a wide array of defense mechanisms, both direct and indirect, to suppress the ability of Tcells to reach the tumor bed and mount curative responses upon infiltration. In addition, patient and tumor genetics, previous antigenic experience, and the microbiome, are all important factors in shaping the T-cell repertoire and sensitivity to immunotherapy. Here, we review the mechanisms that regulate T-cell homing, infiltration, and activity within the solid tumor bed. Finally, we summarize different immunotherapies and combinatorial treatment strategies that enable the immune system to overcome barriers for enhanced tumor control and improved patient outcome.
T 细胞在癌症免疫中发挥着关键作用,这一点可以从长期存活患者的肿瘤切除样本中 T 细胞的存在以及各种免疫疗法的显著临床反应中得到证明,这些疗法可以重新激活它们。事实上,肿瘤可以上调多种直接和间接的防御机制,抑制 T 细胞到达肿瘤床并在浸润时产生治愈反应的能力。此外,患者和肿瘤的遗传因素、先前的抗原经验和微生物组都是影响 T 细胞库的形成和对免疫治疗的敏感性的重要因素。在这里,我们回顾了调节 T 细胞归巢、浸润和在实体肿瘤床中活性的机制。最后,我们总结了不同的免疫疗法和联合治疗策略,这些策略使免疫系统能够克服障碍,增强肿瘤控制,改善患者预后。
Ann Oncol. 2017-12-1
Front Immunol. 2021
Annu Rev Med. 2016-11-17
Cytokine Growth Factor Rev. 2017-6-8
Semin Immunol. 2016-2
Nat Rev Immunol. 2025-8-14
Nat Rev Cancer. 2025-3-17